Why the study?
Does intrapericardial carboplatin administration control malignant pericardial effusion in patients with non-small-cell lung cancer?
Population
10 patients with primary non-small-cell lung cancer and massive malignant pericardial effusion causing…
Design
Case_series
Follow-up
until death (median survival 69 days)
Authors
Loading...
May support intrapericardial carboplatin for malignant pericardial effusion in NSCLC; hypothesis-generating and requires prospective validation.
Does intrapericardial carboplatin administration control malignant pericardial effusion in patients with non-small-cell lung cancer?
Intrapericardial administration of carboplatin is a safe and effective palliative treatment for controlling malignant pericardial effusion in terminally ill patients with non-small-cell lung cancer.
Moriya et al. (2000) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: